Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

Abstract

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many relevant gene-drug associations have been discovered, but PGx guided treatment needs to be cost-effective as well as clinically beneficial to be incorporated into standard healthcare. Progress in this area can be assessed by reviewing economic evaluations to determine the cost-effectiveness of PGx testing versus standard treatment. We performed a review of economic evaluations for PGx associations listed in the US Food and Drug Administration (FDA) Table of Pharmacogenomic Biomarkers in Drug Labeling ( http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm ). We determined the proportion of evaluations that found PGx guided treatment to be cost-effective or dominant over the alternative strategies, and we estimated the impact on this proportion of removing the cost of genetic testing. Of the 130 PGx associations in the FDA table, 44 economic evaluations, relating to 10 drugs, were identified. Of these evaluations, 57% drew conclusions in favour of PGx testing, of which 30% were cost-effective and 27% were dominant (cost-saving). If genetic information was freely available, 75% of economic evaluations would support PGx guided treatment, of which 25% would be cost-effective and 50% would be dominant. Thus, PGx guided treatment can be a cost-effective and even cost-saving strategy. Having genetic information readily available in the clinical health record is a realistic future prospect, and would make more genetic tests economically worthwhile. However, few drugs with PGx associations have been studied and more economic evaluations are needed to underpin the uptake of genetic testing in clinical practice.

References 77

1. 1.

   Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J et al. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.

   Not in our library10.1056/nejmoa0706135

2. 2.

   Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004; 428: 486–486.

   Not in our library10.1038/428486a

3. 3.

   Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23–34.

   Not in our library10.1007/s00439-006-0260-8

4. 4.

   U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (accessed on 18 September 2015).

   Not in our library

5. 5.

   Centers for Disease Control and Prevention. Genomic Tests and Family Health History by Levels of Evidence: Public Health Genomics. Available at http://www.cdc.gov/genomics/gtesting/tier.htm (accessed on 17 February 2016).

   Not in our library

6. 6.

   Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, Ovetsky M et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res 2013; 41: 925–935.

   Not in our library10.1093/nar/gks1173

7. 7.

   Haycox A, Pirmohamed M, McLeod C, Houten R, Richards S. Through a glass darkly: economics and personalised medicine. Pharmacoeconomics 2014; 32: 1055–1061.

   Not in our library10.1007/s40273-014-0190-6

8. 8.

   Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004; 5: 1139–1149.

   Not in our library10.1517/14622416.5.8.1139

9. 9.

   Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. PharmacoEconomics 2008; 26: 569–587.

   Not in our library10.2165/00019053-200826070-00005

10. 10.

    Hatz MHM, Schremser K, Rogowski WH. Is individualized medicine more cost-effective? A systematic review. PharmacoEconomics 2014; 32: 443–455.

    Not in our library10.1007/s40273-014-0143-0

11. 11.

    Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang S-Y, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 2014; 16: 251–257.

    Not in our library10.1038/gim.2013.122

12. 12.

    Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 2010; 11: 1573–1590.

    Not in our library10.2217/pgs.10.145

13. 13.

    Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 2010; 11: 643–646.

    Not in our library10.2217/pgs.10.45

14. 14.

    Shabaruddin FH, Fleeman ND, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. PharmacoEcon Personalized Med 2015; 8: 115–126.

    Not in our library10.2147/pgpm.s35063

15. 15.

    Vegter S, Jansen E, Postma MJ, Boersma C. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res 2010; 71: 492–501.

    Not in our library

16. 16.

    Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics 2010; 28: 1001–1013.

    Not in our library10.2165/11537410-000000000-00000

17. 17.

    Nixon J, Stoykova B, Christie J, Glanville J, Kleijnen J, Drummond M. NHS Economic Evaluation Database for healthcare decision makers. BMJ 2000; 321: 32.

    Not in our library10.1136/bmj.321.7252.32

18. 18.

    University of York Centre for Reviews and Dissemination. Welcome to the CRD Database Available at http://www.crd.york.ac.uk/CRDWeb/HomePage.asp (accessed on 30 October 2015).

    Not in our library

19. 19.

    Beresniak A, Medina-Lara A, Auray JP, De Wever A, Praet JC, Tarricone R et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. PharmacoEconomics 2015; 33: 61–69.

    Not in our library10.1007/s40273-014-0216-0

20. 20.

    McCabe C, Claxton K, Culyer A. The NICE Cost-Effectiveness Threshold. PharmacoEconomics 2008; 26: 733–744.

    Not in our library10.2165/00019053-200826090-00004

21. 21.

    Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259–1267.

    Not in our library10.1212/wnl.0b013e31826aac73

22. 22.

    Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2014; 95: 199–207.

    Not in our library10.1038/clpt.2013.190

23. 23.

    Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C et al. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thromb J 2013; 11: 14.

    Not in our library10.1186/1477-9560-11-14

24. 24.

    Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009; 2: 429–436.

    Not in our library10.1161/circoutcomes.108.808592

25. 25.

    Sorich MJ, Horowitz JD, Sorich W, Wiese MD, Pekarsky B, Karnon JD. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics 2013; 14: 2013–2021.

    Not in our library10.2217/pgs.13.164

26. 26.

    Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost 2013; 11: 81–91.

    Not in our library10.1111/jth.12059

27. 27.

    Wiley Online Library, John Wiley & Sons Ltd. HEED: Health Economic Evaluations Database. Available at: http://onlinelibrary.wiley.com/book/10.1002/9780470510933 (accessed on 28 January 2016).

    Not in our library

28. 28.

    Altar CA, Carhart J, Allen JD, Hall-Flavin D, Winner J, Dechairo B. Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol Neuropsychiatry 2015; 1: 145–155.

    Not in our library10.1159/000430915

29. 29.

    Hornberger J, Li Q, Quinn B. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am J Manag Care 2014; 21: e357–e365.

    Not in our library

30. 30.

    You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogenet Genomics 2014; 24: 6–14.

    Not in our library10.1097/fpc.0000000000000014

31. 31.

    Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174: 1330–1338.

    Not in our library10.1001/jamainternmed.2014.2368

32. 32.

    U.S. Food and Drug Administration. Ziagen Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020977s030,020978s034lbl.pdf (accessed on 2 February 2016).

    Not in our library

33. 33.

    23andMe Inc. 23andMe: Welcome. Available at https://www.23andme.com/en-gb (accessed on 1 February 2016).

    Not in our library

34. 34.
    Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe · 2017

    Not checked
35. 35.

    Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at www.genome.gov/sequencingcostsdata (accessed on 27 January 2016).

    Not in our library

36. 36.

    Genomics England: Genomics England is delivering the 100,000 Genomes Project. Available at http://www.genomicsengland.co.uk (accessed on 31 March 2016).

    Not in our library

37. 37.

    Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414–417.

    Not in our library10.1038/clpt.2012.96

38. 38.

    Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14: 335–342.

    Not in our library10.1097/00008571-200406000-00002

39. 39.

    Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22: 2025–2033.

    Not in our library10.1097/qad.0b013e3283103ce6

40. 40.

    Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010; 28: 1025–1039.

    Not in our library10.2165/11535540-000000000-00000

41. 41.

    Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte JA, Rivero-Roman A, Garcia-Bujalance L, Perez-Escolano I et al. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin 2010; 28: 590–595.

    Not in our library10.1016/j.eimc.2009.09.010

42. 42.

    Kapoor R, Martinez-Vega R, Dong D, Tan SY, Leo YS, Lee CC et al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics 2015; 25: 60–72.

    Not in our library10.1097/fpc.0000000000000107

43. 43.

    Tavadia SM, Mydlarski PR, Reis MD, Mittmann N, Pinkerton PH, Shear N et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628–632.

    Not in our library

44. 44.

    Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507–2512.

    Not in our library

45. 45.

    Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004; 43: 156–163.

    Not in our library10.1093/rheumatology/keh001

46. 46.

    Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593–599.

    Not in our library10.1111/j.1365-2036.2004.02124.x

47. 47.

    Dubinsky MC, Reyes E, Ofman J, Chiou C-F, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100: 2239–2247.

    Not in our library10.1111/j.1572-0241.2005.41900.x

48. 48.

    Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24: 767–781.

    Not in our library10.2165/00019053-200624080-00004

49. 49.

    Van Den Akker-Van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez De Mesa E et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783–792.

    Not in our library10.2217/14622416.7.5.783

50. 50.

    Hagaman JT, Kinder BW, Eckman MH. Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010; 188: 125–132.

    Not in our library10.1007/s00408-009-9217-8

51. 51.

    Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health 2014; 17: 22–33.

    Not in our library10.1016/j.jval.2013.10.007

52. 52.

    Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, Teerawattananon Y. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628–1638.

    Not in our library10.1111/epi.12325

53. 53.

    Tiamkao S, Jitpimolmard J, Sawanyawisuth K, Jitpimolmard S. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm 2013; 35: 608–612.

    Not in our library10.1007/s11096-013-9777-9

54. 54.

    Plumpton CO, Yip VL, Alfirevic A, Marson AG, Pirmohamed M, Hughes DA. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia 2015; 56: 556–563.

    Not in our library10.1111/epi.12937

55. 55.

    McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–814.

    Not in our library10.1086/503820

56. 56.

    Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.

    Not in our library10.1038/sj.mp.4001926

57. 57.

    Perlis RH, Patrick A, Smoller JW, Wang PS. When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic[quest] A Cost-effectiveness Analysis Based on Data from the STAR[ast]D Study. Neuropsychopharmacology 2009; 34: 2227–2236.

    Not in our library10.1038/npp.2009.50

58. 58.

    Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 2011; 12: 501–515.

    Not in our library10.3109/15622975.2011.572998

59. 59.

    Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 147–154.

    Not in our library10.1016/j.pnpbp.2011.08.013

60. 60.

    Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health 2011; 14: 483–491.

    Not in our library10.1016/j.jval.2010.11.012

61. 61.

    Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Pharmacoeconomics 2012; 30: 1067–1084.

    Not in our library10.2165/11595080-000000000-00000

62. 62.

    Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012; 32: 323–332.

    Not in our library10.1002/phar.1048

63. 63.

    Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med 2014; 160: 221–232.

    Not in our library10.7326/m13-1999

64. 64.

    Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615–1616.

    Not in our library10.1016/s0140-6736(00)02221-2

65. 65.

    Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005; 25: 427–434.

    Not in our library10.1097/01.jcp.0000177553.59455.24

66. 66.

    Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9: 539–549.

    Not in our library10.2217/14622416.9.5.539

67. 67.

    Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115: 3858–3867.

    Not in our library10.1002/cncr.24428

68. 68.

    Pichereau S, Le Louarn A, Lecomte T, Blasco H, Le Guellec C, Bourgoin H. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. J Pharm Pharm Sci 2010; 13: 615–625.

    Not in our library10.18433/j3wk5s

69. 69.

    Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57: 231–239.

    Not in our library10.1002/pbc.22936

70. 70.

    You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy—a decision analysis. Thromb Haemost 2004; 92: 590–597.

    Not in our library10.1160/th04-03-0161

71. 71.

    Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150: 73–83.

    Not in our library10.7326/0003-4819-150-2-200901200-00005

72. 72.

    Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother 2009; 7: 197–203.

    Not in our library10.1016/j.amjopharm.2009.07.002

73. 73.

    You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009; 86: 540–547.

    Not in our library10.1038/clpt.2009.104

74. 74.

    Meckley L, Gudgeon J, Anderson J, Williams M, Veenstra D. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. PharmacoEconomics 2010; 28: 61–74.

    Not in our library10.2165/11318240-000000000-00000

75. 75.

    You JHS, Tsui KKN, Wong RSM, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 2012; 7: e39640.

    Not in our library10.1371/journal.pone.0039640

76. 76.

    Chong HY, Saokaew S, Dumrongprat K, Permsuwan U, Wu DB, Sritara P et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res 2014; 134: 1278–1284.

    Not in our library10.1016/j.thromres.2014.10.006

77. 77.

    Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics 2015; 16: 137–148.

    Not in our library10.2217/pgs.14.167

Cited by papers we hold 4

• Warfarin resistance: possibilities to solve this problem. A case report · 2022
  Not checked
• Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation · 2019
  Not checked
• Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good · 2019
  No notice
• Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.